Skip to main content

and
  1. No Access

    Article

    Geriatrie und Gesundheitsökonomie

    M. Hartmann, H. Knoth in Der Onkologe (2002)

  2. Article

    Open Access

    Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations

    The purpose of this analysis of health economic studies in the field of oncology was to investigate among sponsored studies whether any relationship could be established between the type of sponsorship and (1)...

    M Hartmann, H Knoth, D Schulz, S Knoth in British Journal of Cancer (2003)

  3. No Access

    Article

    Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation

    A Jenke, J Freiberg-Richter, C Johne, H Knoth, E Schleyer in Bone Marrow Transplantation (2005)

  4. No Access

    Article

    Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia

    F A Fierro, S Brenner, U Oelschlaegel, A Jacobi, H Knoth, G Ehninger, T Illmer in Leukemia (2009)

  5. Article

    Open Access

    Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

    This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in patients with CD34+ myelodysplastic s...

    U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, I-M Klut in Leukemia (2012)

  6. No Access

    Article

    Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

    In patients with relapsed or refractory (r/r) acute myeloid leukemia (AML), long-term disease control can only be achieved by allogeneic hematopoietic stem cell transplantation (HSCT). We studied the safety an...

    J M Middeke, R Herbst, S Parmentier, G Bug, M Hänel, G Stuhler in Leukemia (2016)